Download PDF
Exp Clin Endocrinol Diabetes 2013; 121(10): 624-627
DOI: 10.1055/s-0033-1354356
Article
© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Clinical Effect of Addition of Beraprost Sodium to Pioglitazone Treatment on the Blood Glucose Levels in Patients with Type 2 Diabetes Mellitus

T. Chen
1   Department of Sports Medicine, Graduate School of Medicine, Nagoya University, Nagoya, Japan
,
M. Kusunoki
2   Department of Internal Medicine, Aichi Medical University Medical Clinic, Nagoya, Japan
,
D. Sato
3   Department of Biomedical Information Engineering, Graduate School of Medical Science, Yamagata University, Yamagata, Japan
,
H. Tsutsui
4   Department of Hygiene and Public Health, Teikyo University School of Medicine, Tokyo, Japan
,
T. Nakamura
3   Department of Biomedical Information Engineering, Graduate School of Medical Science, Yamagata University, Yamagata, Japan
,
T. Miyata
5   Department of Vascular Surgery, Graduate School of Medicine, the ­University of Tokyo, Tokyo, Japan
,
Y. Oshida
6   Research Center of Health, Physical Fitness and Sports, Nagoya University, Nagoya, Japan
› Author Affiliations
Further Information

Publication History

received 02 March 2013
first decision 08 June 2013

accepted 06 August 2013

Publication Date:
03 September 2013 (online)

Also available at
    Permissions and Reprints

Abstract

In recent years, the number of patients with type 2 diabetes mellitus caused by insulin resistance has continued to increase in Japan. Insulin resistance is considered to be closely related to the risk of cardiovascular diseases and atherosclerotic diseases, represented by arteriosclerosis obliterans (ASO). Therefore, improvement of insulin resistance is one of the important strategies in the treatment of type 2 diabetes mellitus. At present, α-glucosidase inhibitors, incretin-related drugs, and thiazolidinediones are among the most important oral hypoglycemic drugs used to improve insulin resistance. In this study, the effect of beraprost sodium, a prostaglandin I2 derivative, in the treatment of type 2 diabetes mellitus was investigated. In type 2 diabetic patients with ASO who were under treatment with pioglitazone, additional treatment with beraprost sodium exerted a significant synergistic effect in reducing the serum HbA1c levels as compared to treatment with pioglitazone alone. This result indicates that concomitant administration of pioglitazone and beraprost sodium may be useful in the treatment of diabetes ­mellitus.

Key words

beraprost sodium - pioglitazone - HbA1c - type 2 diabetes
 

  • References

  • 1 Rajwani A, Cubbon RM, Wheatcroft SB. Cell-specific insulin resistance: implications for atherosclerosis. Diabetes Metab Res Rev 2012; 28: 627-634
    CrossrefPubMedGoogle Scholar
  • 2 Sato N, Kaneko M, Tamura M et al. The prostacyclin analog beraprost sodium ameliorates characteristics of metabolic syndrome in obese Zucker (fatty) rats. Diabetes 2010; 59: 1092-1100
    CrossrefPubMedGoogle Scholar
  • 3 Inoue E, Ichiki T, Takeda K et al. Beraprost sodium, a stable prostacyclin analogue, improves insulin resistance in high-fat diet-induced obese mice. J Endocrinol 2012; 213: 285-291
    CrossrefPubMedGoogle Scholar
  • 4 Fujiwara K, Nagasaka A, Nagata M et al. A stable prostacyclin analogue reduces high serum TNF-α levels in diabetic patients. Exp Clin Endocrinol Diabetes 2004; 112: 390-394
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Kubota T, Kubota N, Kumagai H et al. Impaired insulin signaling in endothelial cells reduces insulin-induced glucose uptake by skeletal muscle. Cell Metab 2011; 13: 294-307
    CrossrefPubMedGoogle Scholar
  • 6 Hernanz R, Martín Á, Péres-Girón JV et al. Pioglitazone treatment increases COX-2-derived prostacyclin production and reduces oxidative stress in hypertensive rats: role in vascular function. Br J Pharmacol 2012; 166: 1303-1319
    CrossrefPubMedGoogle Scholar
  • 7 Majima T, Komatsu Y, Doi K et al. Safety and efficacy of low-dose pioglitazone (7.5 mg/day) vs. standard-dose pioglitazone (15 mg/day) in Japanese women with type 2 diabetes mellitus. Endocr J 2006; 53: 325-330
    CrossrefPubMedGoogle Scholar
  • 8 Aso Y, Hara K, Ozeki N et al. Low-dose pioglitazone increases serum high molecular weight adiponectin and improves glycemic control in Japanese patients with poorly controlled type 2 diabetes. Diabetes Res Clin Pract 2009; 85: 147-152
    CrossrefPubMedGoogle Scholar
  • 9 Chatzipanteli K, Rudolph S, Axelrod L. Coordinate control of lipolysis by prostaglandin E2 and prostacyclin in rat adipose tissue. Diabetes 1992; 41: 927-935
    CrossrefPubMedGoogle Scholar